Clinical Research Directory
Browse clinical research sites, groups, and studies.
CES1 Carriers in the PAPI Study
Sponsor: University of Maryland, Baltimore
Summary
This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396). The purpose of this investigation is to assess the impact of genetic variation in the carboxylesterase 1 (CES1) on response to clopidogrel as well as dual antiplatelet therapy (i.e. clopidogrel and aspirin), as assessed by ex vivo platelet aggregometry, in healthy Amish individuals. The investigators hypothesize that participants who carry alleles that modify the activity or expression of CES1 will have altered response to clopidogrel as well as dual antiplatelet therapy.
Official title: Enrichment of CES1 Carriers in the Pharmacogenomics Anti-Platelet Intervention Study
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2019-10-14
Completion Date
2020-01-17
Last Updated
2026-07-31
Healthy Volunteers
Yes
Conditions
Interventions
Clopidogrel
Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
Aspirin
Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.
Locations (1)
Amish Research Clinic
Lancaster, Pennsylvania, United States